Withdrawal of licence extension application for ticagrelor (Brilique) for primary prevention of atherothrombotic events in combination with aspirin

Application withdrawn as benefit seen with ticagrelor and aspirin in the prevention of atherothrombotic events in adults with coronary artery disease and type 2 diabetes who have not previously had a heart attack was not sufficient to outweigh its risks, especially bleeding.

European Medicines Agency